Fortitude Family Office’s LENZ Therapeutics LENZ Stock Holding History

Fortitude Family Office’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1	Closed	-$6	–	2754
2026 Q2	$6	Sell	1 -40	-98%	-$322	﹤0.01%	2260
2026 Q1	$375	Buy	+41	New	+$576	﹤0.01%	1805
2025 Q2	–	Sell	-9	Closed	-$231	–	2156
2025 Q1	$231	Hold	9	–	–	﹤0.01%	1112
2024 Q4	$260	Buy	+9	New	+$274	﹤0.01%	1249

Other funds holding LENZ

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Fortitude Family Office's LENZ Position: Q3 2026 in Review

Fortitude Family Office sold out of LENZ Therapeutics (LENZ) in Q3 2026, closing a stake of 1 share — an estimated $6 sold.

Fortitude Family Office first reported a position in LENZ in Q4 2024 and held it in 4 quarters. The position peaked at $375 in Q1 2026. 5 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

Fortitude Family Office reported no remaining LENZ Therapeutics position as of Q3 2026 after selling out during the quarter.
Fortitude Family Office sold 1 LENZ Therapeutics share in Q3 2026, an estimated $6.
Fortitude Family Office first reported a position in LENZ Therapeutics in Q4 2024 and held it in 4 quarters.
Fortitude Family Office's LENZ Therapeutics position peaked at $375 in Q1 2026.
5 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.